↓ Skip to main content

Dove Medical Press

Article Metrics

Potential use of custirsen to treat prostate cancer

Overview of attention for article published in OncoTargets and therapy, June 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
21 Mendeley
Title
Potential use of custirsen to treat prostate cancer
Published in
OncoTargets and therapy, June 2013
DOI 10.2147/ott.s33077
Pubmed ID
Authors

Celiste Higano

Abstract

Over the last few years, five agents have demonstrated a survival benefit over a comparator treatment or placebo in the treatment of metastatic castration-resistant prostate cancer and have been approved by the US Food and Drug Administration: sipuleucel-T (a dendritic cell immunotherapy); cabazitaxel; abiraterone acetate and enzalutamide (both hormonal agents); and radium 223 (an alpha emitter). The development of these agents pivoted on whether patients had been treated with docetaxel, which remains the first-line chemotherapy of choice. To date, no combination of docetaxel and another active agent has demonstrated superiority to docetaxel alone despite numerous Phase III trials. Clusterin is a cytoprotective chaperone protein that is upregulated in response to various anticancer therapies. When overexpressed, clusterin interferes with apoptotic signaling, thereby promoting cell survival and conferring broad-spectrum resistance in cancer cell lines. Custirsen (OGX-011) is a second-generation 2'-methoxyethyl modified phosphorothioate antisense oligonucleotide that inhibits expression of clusterin. This review presents the preclinical and clinical data that provided the rationale for the combination of custirsen with chemotherapy in ongoing Phase III trials.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 21 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 4 19%
Student > Master 4 19%
Other 3 14%
Student > Ph. D. Student 3 14%
Student > Doctoral Student 2 10%
Other 4 19%
Unknown 1 5%
Readers by discipline Count As %
Agricultural and Biological Sciences 7 33%
Pharmacology, Toxicology and Pharmaceutical Science 4 19%
Medicine and Dentistry 4 19%
Computer Science 1 5%
Biochemistry, Genetics and Molecular Biology 1 5%
Other 2 10%
Unknown 2 10%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 August 2013.
All research outputs
#9,985,580
of 12,475,053 outputs
Outputs from OncoTargets and therapy
#802
of 1,548 outputs
Outputs of similar age
#104,443
of 152,137 outputs
Outputs of similar age from OncoTargets and therapy
#20
of 40 outputs
Altmetric has tracked 12,475,053 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,548 research outputs from this source. They receive a mean Attention Score of 2.4. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 152,137 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.